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ABSTRACT 
Defining the Inclusion/Exclusion (I/E) criteria of a trial is one of the most important steps during 
a trial design. Increasingly complex I/E criteria potentially create information imbalance and 
transparency issues between the people who design and run the trials and those who consume the 
information produced by the trials. In order to better understand and quantify the impact of a 
category of I/E criteria on observed treatment effects, a concept, named the Selection Induced 
Contrast Estimate (SICE) effect, is introduced and formulated in this paper. The SICE effect can 
exist in controlled clinical trials when treatment affects the correlation between a marker used for 
selection and the response of interest. This effect is demonstrated with both simulations and real 
clinical trial data. Although the statistical elements behind the SICE effect have been well studied, 
explicitly formulating and studying this effect can benefit several areas, including better 
transparency in I/E criteria, meta-analysis of multiple clinical trials, treatment effect interpretation 
in real-world medical practice, etc.  
Keywords: Inclusion/Exclusion Criteria, Randomized Clinical Trials, Patient Selection, 
Conditional Mean, Regression towards the Mean.  
  
 
 
1. INTRODUCTION 
Randomized Clinical Trials (RCTs) are considered the gold standard for the identification of 
treatment effect. RCTs always have a set of patient selection criteria, i.e. Inclusion/Exclusion (I/E) 
criteria, to unambiguously define their targeted populations. The identified treatment effects are 
only true for the targeted population (Food and Drug Administration, 2012). Since the I/E criteria 
are often critical for the success of a trial, defining them becomes one of the most important steps 
when designing a trial. I/E criteria also become increasingly complex.    
Complex I/E criteria potentially create information imbalance and transparency issues between the 
people who design and run the trials (e.g. pharmaceutical companies) and the people who consume 
the information produced by the trials (e.g. physicians and patients). Although it is a general 
practice to provide I/E criteria along with study results, people outside sometimes lack the insights 
to understand, among the dozens of I/E criteria, which ones are more critical to the trial results and 
should be followed more strictly than the others. For example, in clinical trials to study insomnia 
drugs, a group of I/E criteria are specified to ensure that the volunteers are indeed insomnia patients. 
Latency to Persistent Sleep (LPS) is to measure of how long it takes for a volunteer to get to stable 
sleep stage. Some trials choose LPS >= 15 minutes as an inclusion criterion, while the others 
choose LPS >= 20 minutes. Not everyone knows that this subtle difference can cause large 
differences in the resultant treatment effect size.  
Lacking the insights into the impact of each I/E criterion can cause serious issues in various 
contexts. It can play a big role in the discrepancy between treatment effects reported from RCTs 
and those observed in real-world data. It also can invalidate research efforts that attempt to borrow 
information from historical trials.  
 
 
Solutions to this complex issue require the collaboration among many parties, including regulatory 
agencies, pharmaceutical companies, clinicians, and statisticians. This paper is an effort to gain 
insights from a statistical perspective into a category of impactful I/E criteria.  
Before diving into the technical details, a simulated 2-arm (i.e. drug vs. control) parallel trial is 
used to illustrate the general idea (see Appendix A for the simulation code). Assume that the trial 
recruits 1000 patients for each treatment arm. Let a random variable (r.v.) x  represent a patient’s 
baseline measurement, while a r.v. y  represents the post-treatment clinical endpoint. Assume that 
x  and y  follow a bivariate normal distribution. If the patient is finally randomized to the control 
arm, the distribution of these two variables is represented in (1a); if the patient is randomized to 
the drug arm, the distribution is represented in (1b). Note that cy denotes the clinical endpoints for 
patients in the control arm, while ty  for the drug arm. (1a) and (1b) show neither treatment changes 
the population mean, which remains 0, and they only slightly alter the variance and correlation of 
the clinical endpoints.  
  
0 1 0.2
~ ( , )
0 0.2 1c
x
N
y
     
     
    
                                                                                               (1a)  
  2
0 1 0.3 1.2
~ ( , )
0 0.3 1.2 (1.2)t
x
N
y
×     
     ×    
                                                                                (1b) 
Since the post-treatment mean difference between yt and yc is 0, the probability for any reasonable 
statistical procedure, e.g. 2-sample t-test or ANCOVA, to claim a significant drug effect should be 
controlled at a prespecified type-1 error rate, normally 5%.  
Now, we introduce a patient selection process (i.e. an inclusion criterion). That is, only the patients 
with 𝑥𝑥 ≥ 0.6 are randomized to one of the two treatment arms. Then, any reasonable statistical 
 
 
procedure will almost surely (with a probability of about 98%) claim a significant drug effect. The 
“discrepancy” between the claimed drug effects with and without the patient selection (i.e. 𝑥𝑥 ≥0.6) arises because the drug effects are regarding different targeted populations. That is, the I/E 
criterion of 𝑥𝑥 ≥ 0.6 is an impactful criterion and deserves special attention.   
The difference in treatment effects between two populations created by different patient selection 
criteria is the focus of this paper. We name this difference as Selection Induced Contrast Estimate 
(SICE) effect, which is subsequently formulated and quantified.  
Explicitly defining this concept and bringing it to the attention of the statistical and medical 
communities have several benefits. First, some therapeutic areas, e.g. neuroscience, are notorious 
for its unpredictable failures in late-stage clinical studies. The drug effect observed in earlier-stage 
clinical studies suddenly “disappears” in later clinical trials. Some of these surprises can be 
explained with the SICE effect.  
Second, as previous mentioned, a better understanding of the SICE effect provides us with insights 
into the impacts of some I/E criteria. The SICE effect allows us to foresee which I/E criteria can 
be more impactful than the others. This knowledge is useful in many applications. For example, 
meta-data analyses often pool results from multiple studies. The SICE effect can help us gain 
insights into selecting the proper studies to pool for meta-analysis.  
In addition, the SICE effect can help to quantify the potential discrepancy between the drug effects 
observed in a clinical trial and those observed in the real-world setting. Although a drug label 
provides detailed information of the drug’s targeted population, prescribers may consider 
expanding use to patients they consider similar. Diseases are often defined broadly in medical 
practice, while clinical trials for drug approval need to select patients base on unambiguous I/E 
 
 
criteria. For example, insomnia is medically defined as “a sleep disorder in which there is an 
inability to fall asleep or to stay asleep as long as desired” (Roth, 2007). In contrast, a trial to test 
an insomnia drug requires specifying an unambiguous insomniac criterion, such as “mean latency 
to persistent sleep (LPS) on both baseline nights of ≥ 20 minutes” (Eisai Inc., 2013). If this drug 
is approved for treating insomnia, it is generally acceptable for a doctor to prescribe the drug 
without requiring the patient to spend two nights at a sleep center to ensure his/her mean LPS of ≥ 
20 minutes. As a result, the population to which doctors prescribe the drug can be different from 
the one tested in the clinical trials. The concept of the SICE effect can help some medical 
communities understand potentially how much the treatment effect observed in practice may differ 
from that reported in the clinical trials.  
The SICE effect is related to, but different from, some other well studied effects induced by a 
selection process, e.g. selection bias and the Heckman correction (Heckman, 1979), Regression 
towards the Mean (RTM) effect (Galton, 1886; Stigler 1997; Barnett, van der Pols, and Dobson, 
2005), etc. The key difference is that these selection-induced effects focus the impact of selection 
on one population, while the SICE effect is about the impact on the mean difference between two 
populations. In fact, an alternative interpretation of the SICE effect is as the difference between 
the RTM effect between the control and the treated population. Both the control and the drug 
groups have a selection procedure, which induces two separate RTM effects in the two groups. 
However, the sizes of the RTM effects can be different in these two groups. The SICE effect is 
indeed the difference between the RTM effects of the two groups. Detailed explanation is provided 
in Subsection 2.1. This alternative perspective highlights the issue that although many (Senn and 
Brown, 1985; Barnett, van der Pols, and Dobson, 2005) suggest that the RTM effect is completely 
corrected by the RTM of the control group, this may not always be the case. Although, compared 
 
 
with the RTM effect, the SICE effect is relatively small in magnitude, it can become statistically 
significant in large-scale confirmatory clinical trials, as will be demonstrated with both simulation 
results in Subsection 2.2 and a clinical trial dataset in Section 4.  
The remainder of this paper is organized as follows. After the SICE effect is formulated and 
discussed in Subsection 2.1, simulations are presented to illustrate how the magnitude of the SICE 
effect is impacted by different study scenarios. The goal of Section 3 is primarily to show that, 
given a selected population, it is hard to correct the SICE effect even under a very strong 
assumption about the data. The materials in this section are not crucial to understand the concept 
of SICE effect. In Section 4, a real clinical trial dataset is used to demonstrate that, due to the SICE 
effect, the impact of different patient selection criteria on the magnitude of the observed treatment 
effect cannot be ignored in larger clinical trials. A summary and more discussions are provided in 
Section 5.  
2. THE SELECTION INDUCED CONTRAST ESTIMATE (SICE) EFFECT 
2.1. Formulating the SICE effect 
Let us assume that the joint distributions of the selection measurement, x , and the clinical endpoint, 
y , of patients being potentially assigned to the control and the treatment groups respectively 
follow the two distributions in (2).  
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where ( )c cΡ θ  is the distribution of the patients in the control group with a set of distribution 
parameters cθ , while ( )t tΡ θ is that of the patients in the treatment group.  
For simpler notation, we subsequently define the two patient populations as pre-selection and post-
selection populations. It is easy to see all the concepts and results are readily applicable to two 
selected populations obtained by different selection criteria.  
Define the treatment effect over the pre-selection population (i.e. the larger population), oe , as 
 [ ] [ ]o t ce y y= −E E , and                                                                                                     (3) 
the treatment effect over the selected sub-population, se , as 
[ | ] [ | ]s t ce y y= ∈Ω − ∈ΩE x E x ,                                                                                     (4) 
where Ω  represents a set of selection criteria. The SICE effect, SICE , is thus defined as  
 𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 ≜ 𝑒𝑒𝑜𝑜 − 𝑒𝑒𝑠𝑠.                                                                                                                (5)  
Thus, if x is not independent of both ty  and cy , SICEE can be non-zero.  
To simplify the subsequent presentation, we focus on one selection criterion at a time, and assume 
that all measurements follow a normal distribution. Equation (2) thus becomes two bivariate 
normal distributions, represented by Equation (6).  
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The remainder of this section assumes that the selection criterion has a form of x a> , where a  is 
a selection threshold. The derivation of the results in this section is provided in Appendix B. 
 
 
Results with other forms of selection criteria, such as x a< , or b x a> > , can be obtained in a 
similar way.  
Under these assumptions, the SICE effect, SICEE , in (5) becomes 
            𝐸𝐸𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆(𝑧𝑧)[𝜌𝜌𝑐𝑐𝜎𝜎𝑐𝑐 − 𝜌𝜌𝑡𝑡𝜎𝜎𝑡𝑡] = 𝑆𝑆(𝑧𝑧)[𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥,𝑦𝑦𝑐𝑐) − 𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥,𝑦𝑦𝑡𝑡)]/𝜎𝜎,                                  (7) 
where cov( , )x y  is the covariance between random variables x  and y ; 𝑧𝑧 = (𝑎𝑎 − 𝜇𝜇)/𝜎𝜎, where 𝜇𝜇 
and 𝜎𝜎 are defined in (6) as the mean and STD of the baseline measure x .  
( ) ( ) / ( )S z z zφ= Φ − , where 1 2( ) ( 2 ) exp( / 2)z zφ π −= −  and ( ) ( )
z
z t dtφ
−∞
Φ = ∫ .  
Equation (7) helps us better understand the SICE effect. First, since ( ) 0S z > , the SICE effect, 
SICEE , is non-zero whenever cov( , ) cov( , )t cx y x y≠ . Second, the difference between 𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥,𝑦𝑦𝑡𝑡) 
and 𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥, 𝑦𝑦𝑐𝑐) decides whether the observed treatment effect in the selected population is inflated 
or deflated by the SICE effect. Third, the SICE effect disappears, if the selection measurement x 
is uncorrelated with the clinical endpoint y. Finally, the fact that ( )S z is a monotonically increasing 
function suggests that the more selective the selection criterion is (i.e. the threshold a  is bigger), 
the more prominent the SICE effect is.  
If cy′ and ty′  represent the responses of the selected patients treated with control or drug 
respectively, and the treatment effect, se , in Equation (4) is estimated using sample means, i.e.  
ˆs t ce y y′ ′= − ,                                                                                                                         (8) 
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′ ′= ∑ , { , }g t c∈ , cN  and tN  are the number of patients recruited in the control 
and the drug groups, respectively, after the selection process.  
 
 
It can be shown that that ˆse  follows a normal distribution with mean, ˆ[ ]seE , and variance, ˆ[ ]seV , 
shown in (9).  
 ˆ[ ]s s o SICEe e e E= = −E                                                                                                         (9a) 
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Equations (3)-(5), (7) and (9) suggest that the SICE effect does not depend on the number of 
patients, while the variance of its estimate decreases with more patients. Thus, there is always a 
chance for a non-zero SICE effect to be statistically significant when the size of the clinical trial 
becomes sufficiently large.  
Equation (9) suggests that a patient selection process has an unpredictable consequence on the 
magnitude of the treatment effect, if the relationship between the baseline measurement 𝑥𝑥 and 
clinical endpoint 𝑦𝑦 is unknown. In a clinical trial similar to our setting, if the treatment effect over 
the pre-selection patient population, oe , is fixed, the estimated treatment effect over the selected 
patient population, ˆse , can be larger or smaller than oe  due to the SICE effect. According to (9a), 
the estimated effect, ˆse , is less than oe , if SICEE >0, and is larger than oe  if SICEE <0. Whether the 
SICE effect, SICEE , is positive or negative is decided by the sign of [𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥,𝑦𝑦𝑐𝑐) − 𝑐𝑐𝑐𝑐𝑐𝑐( 𝑥𝑥, 𝑦𝑦𝑡𝑡)] , 
which is often unknown before the trial. However, in some cases, the relationship between 𝑥𝑥 and 
𝑦𝑦 can be known. For example, if we know 𝑥𝑥 is a biomarker that is positively correlated with the 
drug mechanism (e.g. PD-L1 biomarker regarding anti-PD-L1 treatment), but uncorrelated with 
the control, we will get SICEE <0, and a larger treatment effect in the selected population.  
Secondly, a patient selection process does help reducing the variance of the estimated effect. Let 
us assume that the data of patients before and after a selection process are available, and the 
 
 
treatment effects over pre-selection and post-select populations can be estimated using sample 
means as ˆoe  and ˆse . Equation (8) and (9b) suggests that the variance of the estimate, ˆse , is less 
than that of ˆoe . That is, 
2 2
ˆ ˆ[ ] ( ) [ ]t cs o
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N N
σ σ
< + =V V , since ( )S z z>  and ( ) 0S z > . Therefore, if the 
number of patients in each treatment group is fixed (e.g. pre-specified in a trial protocol), a patient 
selection process will reduce the variance of the estimator, and thus increases the statistical power 
of detecting a treatment effect.  
As mentioned in the Introduction, the SICE effect can also be explained using the concept of the 
RTM effect. The RTM effects for the control and the treatment groups can be represented as 
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If c c t tρ σ ρ σ≠ , the RTM effect of [ | ]x x a>E  of the control group will not cancel out that of the 
treatment group. What is left is exactly the SICE effect, according to (7).  
It is possible to derive similar results for other parametric distributions, such as the central t-
distributions for measurements with a heavy-tail distribution and the non-central t-distributions for 
measurements with an asymmetric distribution. Because the resultant formulas are complex, they 
are not provided in this paper.  Instead, simulation results in Subsection 2.2 are used to demonstrate 
that the SICE effect under a bivariate t-distribution has a similar form as that in (7).    
2.2. Simulation  
First, we study the impacts of data distributions and selection thresholds on the SICE effect. The 
settings of the parameters of the simulation are listed in Table 1.  
 
 
Table 1 
Distribution cµ µ=  tµ  cσ σ=  tσ  cρ  tρ  ( ) /a µ σ−  gN  
( 3)t df = , 
( 8)t df = , 
normal  
0 0 1.00 
0.50, 
0.85, 
1.00, 
1.15, 1.50 
0.2 0.1, 0.2,     0.3, 0.6 
q(0.25), 
q(0.5), 
q(0.75) 
1500 
 
In Table 1, ( )t df n= denotes a t-distribution with degrees of freedom of n, n=3 or 8. ( )q p  denotes 
the quantile of a probability, p, under the corresponding data distribution, and p = 0.25, 0.5, or 
0.75. It is used to determine the select threshold a . For example, when p=0.25, the selection 
threshold a should be set so that 25% patients would be excluded by the selection procedure. gN
is the number of patients in the control or the treatment group. cµ µ=  and cσ σ=  ensure that the 
selection measurement and the clinical endpoint at the control group follow two identical 
distributions.  
The parameters in Table 1 produce 180 different parameter combinations, i.e. simulation scenarios. 
For each simulation scenario, 2000 trials were simulated. According to (3), (4), (5), (8), and (9a), 
the estimate of the SICE effect, ˆSICEE , is a function of the parameters in Table 1, and is calculated 
as  
2000 2000
( ) ( )
1 1
ˆ ˆ ˆ/ 2000 / 2000 ( )i iSICE SICE s t c
i i
E E e µ µ
= =
= = − −∑ ∑ ,             
where ( )ˆ ise  and 
( )ˆ i
SICEE are, respectively, the estimate of the treatment effect for the selected patients 
and that of the corresponding SICE effect in the ith trial out of the 2000 trials. ( )ˆ iSICEE asymptotically 
follows a normal distribution and is claimed to be significant if a null hypothesis of ( )ˆ 0iSICEE = is 
 
 
excluded with a significance level of 0.05. The probability of ˆSICEE being significant can be 
calculated as the ratio of the number of simulated trials, whose estimate, ( )ˆ iSICEE , is statistically 
significant, to the total number of simulated trials, i.e. 2000 in this case. This measurement can 
also be considered as the type-1 error of the treatment effect over the pre-selection population, oe , 
caused by the SICE effect.  
Estimate ( )ˆ ise was obtained using both the 2-sample t-test and the ANCOVA method. Both methods 
produced almost the same results, and the results of the ANCOVA method are just slightly less 
variable. Thus, only the results of the ANCOVA method are reported in Figure 1 to keep it concise.  
The left panel of the Figure 1 suggests that the SICE effect under a t-distribution should have a 
similar form as (7), and can be represented as𝑓𝑓(𝑎𝑎,𝑑𝑑𝑓𝑓)[𝜌𝜌𝑐𝑐𝜎𝜎𝑐𝑐 − 𝜌𝜌𝑡𝑡𝜎𝜎𝑡𝑡], where ( , )f a df  denotes a 
function increasing with the selection threshold, a , but decreasing with degrees of freedom, df , 
of the t-distribution. That is, both stricter selection criteria and heavier tail in the data distribution 
make the SICE effect larger. The right panel of Figure 1 shows that, with a high probability, the 
SICE effect can cause that a treatment effect is declared in the selected population when the true 
difference between the means in the pre-selection population is zero.  
 
 
 
Figure 1 The SICE effect under different data distributions and selection thresholds 
Next, we study the impact of the number of patients in each treatment group on the estimated 
treatment effect induced by the SICE effect. The simulation settings are specified in Table 2, and 
their results are in Figure 2. Note that the magnitude of the estimated SICE effect is the same as 
that of the estimated treatment effect in this setting, since 0oe = .  
Table 2 
Distribution cµ µ=  tµ  cσ σ=  tσ  cρ  tρ  ( ) /a µ σ−  gN  
normal  0.0 0.0 1.00 
0.50, 
0.85, 
1.00, 
1.15, 1.50 
0.2 
0.1, 
0.2,     
0.3, 0.6 
q(0.5) 
20, 50, 
150, 500, 
1000, 
2000, 
5000 
  
 
 
 
Figure 2 The SICE effect under different numbers of patients 
According to (7), the SICE effect, SICEE , is a linear function of 𝜌𝜌𝑐𝑐𝜎𝜎𝑐𝑐 − 𝜌𝜌𝑡𝑡𝜎𝜎𝑡𝑡, and is not a function 
of number of patients. Thus, the value of the estimated SICE effect, ˆSICEE , is plotted at the upper 
x-axis.  
The simulation results suggest that, when the size of clinical trials becomes larger, the probability 
for the SICE effect to be significant becomes increasingly pronounced, even for the cases where 
t t c cρ σ ρ σ− is small.   
Note that the curves of ˆPr( )SICEE Being Significant− −  in Figure 1 and 2 all have some unsmooth 
jumps at 0.1t t c cρ σ ρ σ− = , -0.05, and -0.1. Let’s take 0.1t t c cρ σ ρ σ− =  as an example to explain 
the jumps. More than one parameter combinations in Table 1 and 2, e.g 0.2, 1.5t tρ σ= = and
 
 
0.3, 1t tρ σ= = , can produce 0.1t t c cρ σ ρ σ− = . Although the estimated SICE effect, ˆSICEE , in both 
cases are the same, the probability for ˆSICEE to be significant is smaller for the cases where tσ is 
larger,  because the variance of ˆSICEE increases with tσ  according to (9b). This causes the jumps 
in the curves in both figures. 
3. A METHOD TO ESTIMATE THE TREATMENT EFFECT IN THE PRE-SELECTION 
POPULATION 
This section attempts to address a question: given a selected population and some strong 
assumptions on the data, is it possible to mitigate the SICE effect? As previously mentioned, 
materials in this section are not crucial for understanding the concept of SICE effect.  
3.1. A Maximum Likelihood method to estimate the treatment effect in the pre-selection 
population  
The SICE effect quantifies the discrepancy in treatment effects observed over the pre-selection 
population and the post-selection population. In some cases, the ability to estimate the treatment 
effect in the pre-selection population, oe , using the available post-selection population becomes 
desirable. For example, if the treatment effect, oe , is estimated to be significant, the population 
targeted by the treatment may be expanded by removing a selective criterion. Also, the estimate 
of oe  can provide a quantitative measure on how likely the drug can be effective regarding the pre-
selection population.  
The data distribution of the pre-selection population should be assumed to follow distributions 
with a finite number of parameters to make it possible to estimate oe  only with the data of the 
selected patients. Again, a bivariate normal distribution is assumed, because abundant 
mathematical tools are available in this context (Senn and Brown, 1985; James, 1973; Cohen, 1955; 
Cohen, 1957). Senn and Brown (1985) suggest that the maximum likelihood (ML) estimator 
 
 
proposed in Cohen (1955), which we name as “Cohen ML” for short, is a better method than the 
method of moment approach proposed in James (1973). Thus, we subsequently focus on the Cohen 
ML estimator. In order to make this paper self-contained, some equations in Cohen (1955) are 
duplicated in this section.  
A number of notation conventions are used. x , ty  and cy denote measurements in the pre-
selection population, while cx′ , tx′ , cy′  and ty′  denote the measurements of the selected patients in 
the control or the treatment groups. Also, bˆ indicates the estimate of the parameter b , while b
indicates the sample statistics directly computed from the collected data. Accordingly, { , }g t c∈ , 
,
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x x N
=
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According to (3),  
  ˆ ˆ ˆ( ) ( )o t ce m y m y= −                                                                                                             (11) 
Where ˆ ( )gm y  is the ML estimate of [ ]gyE . 
The mean of the clinical endpoint over the pre-selection population, ˆ ( )gm y , can be calculated from 
the estimates of the mean, ˆ ( )m x , and standard deviation, ˆ ( )xσ , of the selection measurement, x . 
They are provided in Cohen, 1955 as, 
1ˆ ˆ ˆ( ) / [ ( ) ]x S z zσ ν= − ,                                                                                                       (12) 
ˆ ˆ ˆ( ) ( )m x a x zσ= − ,                                                                                                             (13) 
where zˆ is obtained by solving an estimating equation in (14), 
 
 
2 2
2 1ˆ ˆ ˆ ˆ ˆ[1 ( ( ) )] / ( ( ) ) / 0z S z z S z z ν ν− − − − = ,                                                                        (14) 
where 
1
( ) /
gN
k
k i g
i
x a Nν
=
′= −∑ , and {1, 2}k ∈ .  
Only when the distribution of the selection measurement, ix , fairly closely follows a normal 
distribution, will Equation (14) have a valid root.  This is one of major constraints that numerically 
prevent the Cohen ML method from being used in the cases where the data do not follow a normal 
distribution.  
ˆ ( )gm y can then be estimated from ˆ ( )m x and the data as  
ˆˆˆ ˆ( ) [ ( ) ]g g g gm y m x xα β′= + − ,                                                                                             (15) 
where ˆg gyα ′= , ˆ ( , ) ( ) / ( )g g g g g gr x y s y s xβ ′ ′ ′ ′= . 
Since ˆgα , ˆgβ , ˆ ( )m x , and ˆ ( )gm y  are all ML estimators, and, under the large sample assumption, 
they all approximate normal distributions. Cohen (1955) also shows that ˆgα , ˆgβ , and ˆ ( )m x are 
uncorrelated with each other. If the number of patients for each treatment group, gN  ,  is pre-
determined in the trial protocol, the asymptotic variances of these estimates are provided in Cohen 
(1955) as,  
 2ˆ[ ] /g g gNα σ=V                                                                                                                (16) 
 2 2 11ˆ ˆ[ ] / [ ( ) ( )]g g gx N zβ σ σ φ=V                                                                                            (17) 
 2 222 11 22 12ˆ ˆ ˆ ˆ ˆ[ ( )] ( ) ( ) / [ ( ( ) ( ) ( ) )]gm x x z N z z zσ φ φ φ φ= −V                                                         (18) 
where 11 ˆ ˆ ˆ ˆ( ) 1 ( )[ ( ) ]z S z S z zφ = − − , 12 ˆ ˆ ˆ ˆ ˆ( ) ( ){1 [ ( ) ]}z S z z S z zφ = − − , and 22 12ˆ ˆ ˆ( ) 2 ( )z z zφ φ= + . 
 
 
It is possible to derive the closed form of the variance of ˆ ( )gm y , i.e. ˆ[ ( )]gm yV , based on (15) and 
the uncorrelated relationship between ˆgα , ˆgβ , and ˆ ( )m x . However, the resultant form is too 
complicated to provide us with more insights, and thus omitted here. In fact, a straightforward way 
to calculate ˆ[ ( )]gm yV  is using the Monte Carlo method. Since ˆgα , ˆgβ , and ˆ ( )m x  follow a 
univariate normal distribution with parameters estimable from (13)-(18), it is possible to generate 
samples of ˆ ( )gm y  according to (15). ˆ[ ( )]gm yV  can then be computed from the samples using the 
Monte Carlo method.  
According to (11), the distribution of the estimate of the treatment effect, ˆoe , should also be 
asymptotically normal. Its variance is  
ˆ ˆ ˆ[ ] [ ( )] [ ( )]o t ce m y m y= +V V V ,                                                                                           (19) 
since ˆ ( )tm y  and ˆ ( )cm y are uncorrelated from each other.  
3.2. Simulation 
First, we would like to evaluate the bias and the statistical power of the Cohen ML method. The 
simulation settings are specified in Table 3.  
Table 3 
Distribution cµ µ=  tµ  cσ σ=  tσ  cρ  tρ  ( ) /a µ σ−  gN  
normal  0.00 
0.00, 
0.15, 
0.50 
1.00 
0.50, 
0.85, 
1.00, 
1.15, 1.50 
0.2 
0.1, 
0.2,     
0.3, 0.6 
q(0.5), 
q(0.25) 
250, 500, 
1000, 
2000  
 
 
 
The parameters in Table 3 can produce 480 parameter combinations, i.e. simulation scenarios. For 
each simulation scenario, 2000 trials are simulated. The bias is a function of the parameters in 
Table 3, and can be calculated as  
[ ]
2000
( )
1
ˆ ˆ / 2000io o o o
i
Bias e e e e
=
= − = −∑E , 
where ( )ˆ ioe  is the estimated treatment effect over the pre-selection population in the ith trial using 
the Cohen ML method, and ( )o t ce µ µ= −  is the true treatment effect over the pre-selection 
population.   
In order to provide a reference estimator for the Cohen ML method to compare with, a scenario 
suitable for using the conventional ANCOVA method was included. In this scenario, the patient 
selection procedure is removed. For each treatment group, gN patients are simulated, and they all 
go through the treatment stage.   
Under the null hypothesis of no bias, i.e. [ ]ˆ 0o oe e− =E , [ ]ˆoeE is claimed to be statistically 
significantly different from oe  if the p-value of a t-test of 
( )ˆ io oe e− , 1 2000i =  , is smaller than 
0.05.  
The simulation results about the estimation bias are reported in Figure 3. Like the simulation results 
presented in Subsection 2.2, the x-axis is defined as t t c cρ σ ρ σ− . Our simulation shows that the 
biases are the same for three different choices of tµ , i.e. 0.00tµ = , 0.15, or 0.50. Therefore, only 
the results of the cases where 0.00tµ =  are presented in Figure 3.  
Figure 3 has three panels. The first two panels present the simulation results obtained using Cohen 
ML method with two different selection thresholds, while the third panel presents the results 
 
 
obtained using the ANCOVA method to act as a reference. Each panel includes four groups of 
simulation results, and each group of results have the same number of patients, gN . A smoothed 
curve is produced using the LOESS method for each group of results to highlight their general 
trends.  
The results in Figure 3 show that the biases of the Cohen ML method are generally small and non-
significant if the number of patients is sufficiently large, and the selection criterion is not very 
exclusive. The more selective the criterion is, the larger the bias is. Also, the bias is larger when 
the number of patients is relatively smaller. In addition, the simulation results suggest that the 
magnitude of the bias increases with the absolute values of t t c cρ σ ρ σ− .  
 
 
 
 
Figure 3 The bias of the Cohen ML method 
In order to evaluate the statistical power of the Cohen ML method, we focus on the 180 simulation 
scenarios with 0.15tµ = . The statistical power is estimated as  
  
2000
( )
0.05
1
ˆ( ) / 2000io
i
Power I e
=
= ∑ , 
where ( )0.05 ˆ( )
i
oI e is an indicator function, which is 1 when the estimate 
( )ˆ ioe is statistically 
significantly different from 0 at a significance level of 0.05, and 0 otherwise. The results are 
reported in Figure 4. 
 
 
Figure 4 has 8 panels arranged in four rows and two columns. The two panels at each row have 
the same number of patients, while the four panels at each column have the same selection criterion. 
Within each panel, results with the same tσ value are plotted as a single curve.  
Results in Figure 4 suggest that the statistical power of the Cohen ML method increases with a 
larger number of patients and decreases with a more selective criterion. Also, the power decreases 
with a larger variance of the clinical endpoints in the treatment group, tσ , and increase with a 
smaller correlation between selection measurements and clinical endpoints, tρ . In a favorable 
scenario, e.g. (0.15), 2000ga q N= = , the power of Cohen ML can approach 1.0. In contrast, in a 
less favorable scenarios, e.g. (0.5), 250ga q N= = , the average power can be as low as about 0.1.  
 
 
 
 
Figure 4 The power of the Cohen ML method 
The simulations so far are based upon the assumption that the data strictly follow a bivariate normal 
distribution. To evaluate how much the Cohen ML method can tolerate a data distribution that 
deviates from this assumption, 120 simulation scenarios with the parameter combinations defined 
in Table 4 were used.  A bivariate t-distribution with degrees of freedom of 8 is used to simulate 
2000 trials for each simulation scenario. Since the bias is the same for the three choices of tµ , i.e. 
0.00tµ = , 0.15, or 0.50, only the results with 0.00tµ =  are presented in Figure 5.  
 
 
 
 
Table 4 
Distribution cµ µ=  tµ  cσ σ=  tσ  cρ  tρ  ( ) /a µ σ−  gN  
( 8)t df =  0.00 
0.00, 
0.15, 
0.50 
1.00 
0.50, 
0.85, 
1.00, 
1.15, 
1.50 
0.2 
0.1, 
0.2,     
0.3, 0.6 
q(0.5), 
q(0.25) 1000  
 
Results in Figure 5 show that the bias estimated using the Cohen ML method is large and is 
significantly different from 0 when 0t t c cρ σ ρ σ− ≠ . In contrast, the ANCOVA method tolerates 
the deviation in data distribution well, and its bias estimates remain close to 0.  In fact, when a 
bivariate t-distribution with smaller degrees of freedom, e.g. 3 or 4, was used to simulate the data, 
the Cohen ML method in many cases numerically failed because Equation (14) did not have a 
valid root in those cases.  
 
 
 
 
Figure 5 Large biases produced by the Cohen ML method with non-normal distributions 
In summary, simulation results in this subsection suggest that, using existing Cohen ML method, 
it is hard to mitigate the SICE effect even under a very strong assumption on the data. It is 
somewhat possible only when the data are strictly normal, the selection criterion is mild, and the 
size of the trial is large.  
4. APPLICATION TO A REAL DATASET 
In this section, a clinical trial dataset from a real drug development program is used to illustrate 
the impact of the SICE effect. The involved compound, coded as MK in this paper, was developed 
until 2007 as a treatment for insomnia.   
This dataset was from a placebo-controlled randomized parallel trial, which included both a 
treatment arm of MK and a placebo arm. Each patient slept at a sleep center on two separate visits 
to measure their objective sleep quality, including Latency to Persistent Sleep (LPS). The first visit 
 
 
happened before the patient took any treatment and was used as the baseline night. During the 
second visit, the patient first took either MK or placebo according to the treatment group he/she 
was randomized to MK or placebo, and then his/her sleep quality was measured for the second 
time. As a treatment for insomnia, MK was expected to make patients to fall asleep faster. That is, 
compared with the patients in the placebo group, those in the MK group were expected to have 
smaller LPS.  
It is a fairly common practice in insomnia clinical trials that patients are evaluated and selected at 
the baseline to make sure they are indeed primary insomnia patients. One of the frequently used 
criteria is to select only patients whose LPS exceeds a threshold, say T. That is, that a patient needs 
at least T minutes to enter stable sleep.  However, there is no agreement between practitioners on 
the exact value of T. Therefore, some trials use 15 minutes, while the others 20 minutes, as the 
threshold. It is subsequently demonstrated that, due to the SICE effect, different choices of the 
threshold T can have a dramatic impact on the size of the observed drug effect. 
In order to make the LPS data more normal, a log-transform is first applied to them. The drug 
effects are estimated using both the t-test and the ANCOVA method. The drug effect over the pre-
selection population is first estimated. After that, a selection procedure is introduced at the baseline 
with 6 different selection thresholds ranging from 15 minutes to 20 minutes, i.e. T= 15, 16, …, 20. 
The drug effect under each threshold is then estimated based upon the corresponding selected 
patients.  The results obtained using both t-test and ANCOVA methods are reported in Figure 6. 
The point estimate is marked, along with its 95% confidence interval. The number of patients in 
each treatment group under each selection threshold is shown at the top of the figure.  
 
 
Figure 6 shows that, due to the SICE effect, the observed MK drug effect is generally increased 
with more selective thresholds. The observed MK’s effect on LPS when T=15 minutes is 39% 
larger than that in the scenario without patient selection. In contrast, the observed MK’s effect 
when T=20 minutes is 106% larger. The concept of the SICE effect helps us understand that the 
selection threshold T plays such an important role in the size of the observed drug effect. In other 
words, the observed drug effect can be very sensitive to the choice of selection threshold in this 
dataset.  
Based on this observation, we recommend that, when analyzing a large confirmatory clinical trial, 
if possible, we should repeat the analysis several times with different selection thresholds, or 
adjusted versions, of each inclusion/exclusion criterion to evaluate how sensitive the observed 
treatment effect is to this particular selection criterion. For example, if this trial originally used a 
threshold of 15 minutes, and thus it only collected subjects whose baseline LPS is no fewer than 
15 minutes, it is still possible to implement our recommendation by increasing the baseline LPS 
thresholds from 16 to 20 minutes using the available data.  
 
 
 
Figure 6 Observed MK’s effect on LPS with or without patient selection 
Since the log-transformed LPS data approximately follow a normal distribution, the Cohen ML 
method is applied to estimate the MK’s effect over the pre-selection population at each chosen 
LPS threshold. The estimates, along with their 95% confidence intervals, are reported in Figure 7. 
The drug effect directly estimated with the pre-selection population is also reported in Figure 7 for 
comparison. Figure 7 confirms our observation in Section3, and suggests that, compared with the 
estimate obtained with the original dataset, the estimates obtained from the selected populations 
have relatively large biases and wide 95% confidence intervals, and are thus not very informative.  
 
 
 
Figure 7 MK’s effect over pre-selection population estimated using Cohen ML method 
 
5. SUMMARY AND DISCUSSION 
In order to better understand the impact of a patient selection criterion on the treatment effect from 
a RCT, a concept, called the SICE effect, is introduced and formulated in this paper. The effect 
occurs when the covariance of the measurements with a variable used for selection are different 
between treatment groups. Since this effect is proportional to the difference between two 
covariance estimates, its magnitude is usually not large, and its impact is expected to become 
evident primarily in large-scale confirmatory clinical trials.  
One of our major motivations to study the SICE effect is to advocate for a more transparent 
understanding of the I/E criteria in RTCs. Both the simulation results and the results from a clinical 
 
 
trial dataset demonstrate that, due to the SICE effect, a selection criterion can have a surprisingly 
large impact on the magnitude of the observed treatment effect. Based upon this observation, when 
possible, the sensitivity of an observed treatment effect on a selection criterion should be evaluated 
by repeating the data analysis with several adjusted versions of the selection criterion, e.g. using 
different thresholds in the selection criterion. Those I/E items that can substantially impact the 
observed treatment effects should be duly noted.   
The SICE effect is studied in this paper under an assumption that the measurements are numeric 
variables, which follow bivariate normal distributions. However, the concept of the SICE effect 
exists in clinical trials with other types of clinical outcomes, such as probability for an event to 
happen, time to event, etc. Insights gained in this paper could be expanded to other types of clinical 
outcomes.  
The essence of the SICE effect has implications on other statistical areas, such as missing data 
analysis. For example, in a large trial studying a pain treatment, those patients suffering more 
severe pains have a higher probability to drop out.  The effect of drop-outs can be viewed as a 
patient selection procedure with a soft/fuzzy threshold. When analyzing this type of data, besides 
considering other known effects, it may be beneficial to also pay attention to the SICE effect 
induced by the drop-outs.  
APPENDIX 
Appendix A: R code of the simulated simple two-treatment parallel trial   
 library(MASS) 
# To set up the parameters of two bivariate norm distributions 
M1 = array(0,c(2,1)); 
Sigma1 = matrix(c(1,0.2,0.2,1), ncol=2); 
 
 
 
M2 = array(0,c(2,1)); 
Sigma2 = matrix(c(1,0.3*1.2,0.3*1.2,1.2^2), ncol=2); 
# To set up the threshold 
a = 0.6; 
# To define the number of patients planning to recruit for each treatment group. 
nSubj = 1000; 
set.seed(500);  
# To generate the pre-selection population 
nTotalSubj = round(nSubj/(1-pnorm(a, mean = 0, sd = 1))); 
PBO0 = mvrnorm(nTotalSubj, M1, Sigma1); 
DRUG0 = mvrnorm(nTotalSubj, M2, Sigma2); 
# The selection procedure  
PBO = PBO0[PBO0[,1]>a, 2] 
Drug = DRUG0[DRUG0[,1]>a, 2] 
# estimate treatment effect using a 2-sample t.test 
tRes =  t.test(Drug, PBO) 
   
Appendix B: Derivations of the results in Section 2.1.  
Let two i.i.d. random variables 1 ,2, (0,1)gz z N , and { , }g t c∈ . Using Cholesky decomposition, (6) 
can be reformulated as 
1
2
,2
0
1g g gg g g g
x z
y z
σµ
µ ρ σ σ ρ
      
= +       −       
,  
which is equivalent to  
1
2
1 ,21g g g g g g g
x z
y z z
µ σ
µ ρ σ σ ρ
= +
= + + −
.                                                                                   (20) 
 
 
Equation (20) implies that x and ,2gz are independent from each other, and thus ,2[ | ] 0gz x a> =E . 
Therefore, 1[ | ] [ | ]g g g gy x a z x aµ ρ σ> = + >E E ,                                                                        (21) 
where 1 1 1[ | ] [ | ] ( )
a az x a z z Sµ µ
σ σ
− −
> = > =E E ,  according to (20).                        
Bringing (21) into (4), and then into (5) along with (3), (7) can be obtained.                
To avoid the tedious derivation of the conditional variance of gy , [ | ]gy x a>V , we directly cite 
its form from Heckman (1979) as  
2 2 2[ | ] ( )( ( ) )g g g gy x a S z S z zσ ρ σ> = − −V .                                                                         (22) 
Since cy′ and ty′  are two independent samples,  according to (8),  
ˆ[ ] [ ] [ ] [ | ] / [ | ] /s t c t t c ce y y y x a N y x a N′ ′= + = > + >V V V V V .                                           (23) 
Equation (9b) can be obtained by bringing (22) into (23).                                            
Bringing the first equation in (20) into (10), it can be obtained that  
 1
[ | ]
[ | ] [ | ]g g g g
g
y x a x x a z x a
µ µρ ρ
σ σ
> − −
= > = >
E
E E , 
which is exactly the same as (21). Thus, the difference between (10b) and (10a) is exactly (7).       
  
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